JP7261583B2 - 補体媒介性疾患を処置するための組成物及び方法 - Google Patents

補体媒介性疾患を処置するための組成物及び方法 Download PDF

Info

Publication number
JP7261583B2
JP7261583B2 JP2018515539A JP2018515539A JP7261583B2 JP 7261583 B2 JP7261583 B2 JP 7261583B2 JP 2018515539 A JP2018515539 A JP 2018515539A JP 2018515539 A JP2018515539 A JP 2018515539A JP 7261583 B2 JP7261583 B2 JP 7261583B2
Authority
JP
Japan
Prior art keywords
complement
mice
variant
aav
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018515539A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527941A (ja
JP2018527941A5 (enExample
Inventor
宋文超
ガリパリ，ダモダル
三輪隆史
Original Assignee
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア filed Critical ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア
Publication of JP2018527941A publication Critical patent/JP2018527941A/ja
Publication of JP2018527941A5 publication Critical patent/JP2018527941A5/ja
Priority to JP2021128847A priority Critical patent/JP7324253B2/ja
Application granted granted Critical
Publication of JP7261583B2 publication Critical patent/JP7261583B2/ja
Priority to JP2023123167A priority patent/JP2023139256A/ja
Priority to JP2024209719A priority patent/JP2025029082A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018515539A 2015-09-24 2016-09-23 補体媒介性疾患を処置するための組成物及び方法 Active JP7261583B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021128847A JP7324253B2 (ja) 2015-09-24 2021-08-05 補体媒介性疾患を処置するための組成物及び方法
JP2023123167A JP2023139256A (ja) 2015-09-24 2023-07-28 補体媒介性疾患を処置するための組成物及び方法
JP2024209719A JP2025029082A (ja) 2015-09-24 2024-12-02 補体媒介性疾患を処置するための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562232008P 2015-09-24 2015-09-24
US62/232,008 2015-09-24
PCT/US2016/053347 WO2017053732A2 (en) 2015-09-24 2016-09-23 Composition and method for treating complement-mediated disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021128847A Division JP7324253B2 (ja) 2015-09-24 2021-08-05 補体媒介性疾患を処置するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2018527941A JP2018527941A (ja) 2018-09-27
JP2018527941A5 JP2018527941A5 (enExample) 2019-11-07
JP7261583B2 true JP7261583B2 (ja) 2023-04-20

Family

ID=58387476

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018515539A Active JP7261583B2 (ja) 2015-09-24 2016-09-23 補体媒介性疾患を処置するための組成物及び方法
JP2021128847A Active JP7324253B2 (ja) 2015-09-24 2021-08-05 補体媒介性疾患を処置するための組成物及び方法
JP2023123167A Pending JP2023139256A (ja) 2015-09-24 2023-07-28 補体媒介性疾患を処置するための組成物及び方法
JP2024209719A Pending JP2025029082A (ja) 2015-09-24 2024-12-02 補体媒介性疾患を処置するための組成物及び方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021128847A Active JP7324253B2 (ja) 2015-09-24 2021-08-05 補体媒介性疾患を処置するための組成物及び方法
JP2023123167A Pending JP2023139256A (ja) 2015-09-24 2023-07-28 補体媒介性疾患を処置するための組成物及び方法
JP2024209719A Pending JP2025029082A (ja) 2015-09-24 2024-12-02 補体媒介性疾患を処置するための組成物及び方法

Country Status (11)

Country Link
US (4) US10988519B2 (enExample)
EP (1) EP3359663A4 (enExample)
JP (4) JP7261583B2 (enExample)
KR (1) KR102773865B1 (enExample)
CN (2) CN108291216B (enExample)
AU (3) AU2016326627B2 (enExample)
CA (1) CA2999299A1 (enExample)
HK (1) HK1251482A1 (enExample)
IL (2) IL296929B2 (enExample)
RU (1) RU2727411C2 (enExample)
WO (1) WO2017053732A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023139256A (ja) * 2015-09-24 2023-10-03 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 補体媒介性疾患を処置するための組成物及び方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201706808D0 (en) * 2017-04-28 2017-06-14 Univ Newcastle Modified complement proteins and uses thereof
WO2019079718A1 (en) * 2017-10-20 2019-04-25 Gemini Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION
GB201800620D0 (en) * 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
EP3894568A2 (en) * 2018-12-12 2021-10-20 Flagship Pioneering Innovations V, Inc. Anellosomes for delivering secreted therapeutic modalities
GB201821082D0 (en) * 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Combination of complement factors i and h, and vector encoding thereof
CN113924313A (zh) * 2019-04-10 2022-01-11 马萨诸塞大学 因子h载体及其用途
IL292379A (en) * 2019-10-22 2022-06-01 Applied Genetic Tech Corporation Adeno-associated virus (aav)vectors for the treatment of age-related macular degeneration and other ocular diseases and disorders
EP4048319A1 (en) * 2019-10-23 2022-08-31 Gemini Therapeutics Sub, Inc. Methods for treating patients having cfh mutations with cfh-encoding vectors
IL299048A (en) 2020-06-14 2023-02-01 Vertex Pharma Variants of complement factor - 1 fusion structures and preparations containing them and their uses
GB202010009D0 (en) * 2020-06-30 2020-08-12 Syncona Investment Man Ltd Vector
EP4284335A1 (en) 2021-02-01 2023-12-06 RegenxBio Inc. Gene therapy for neuronal ceroid lipofuscinoses
KR20240112733A (ko) 2023-01-11 2024-07-19 포항공과대학교 산학협력단 조현병의 예방 또는 치료용 나노바디
EP4714980A1 (en) * 2023-05-19 2026-03-25 Starrygene Therapeutics Co., Ltd. Aav vector for treating alternative complement pathway-related diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515474A (ja) 2009-12-24 2013-05-09 ザ ユニヴァーシティ コート オブ ザ ユニヴァーシティ オブ エディンバラ 組換え体ｈ因子ならびにそのバリアントおよびコンジュゲート
US20150110766A1 (en) 2012-03-19 2015-04-23 University Ulm Regulator of complement activation and uses thereof
WO2015092335A2 (fr) 2013-12-20 2015-06-25 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Proteines recombinantes possedant une activite de facteur h

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5679546A (en) 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
AU728220B2 (en) 1997-04-14 2001-01-04 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant AAV product
EP1080218A1 (en) 1998-05-27 2001-03-07 University of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient
ATE454445T1 (de) 1998-11-10 2010-01-15 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
EP2369002A1 (en) 1999-08-09 2011-09-28 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
CA2410901C (en) 2000-06-01 2012-03-20 University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
SG10202108118RA (en) 2001-11-13 2021-08-30 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
ES2975413T3 (es) 2001-12-17 2024-07-05 Univ Pennsylvania Secuencias de serotipo 8 de virus adenoasociado (AAV), vectores que las contienen y usos de las mismas
US20070015238A1 (en) 2002-06-05 2007-01-18 Snyder Richard O Production of pseudotyped recombinant AAV virions
HUE054805T2 (hu) 2003-09-30 2021-09-28 Univ Pennsylvania Adeno-asszociált vírus (AAV) kládok, szekvenciák, az azokat tartalmazó vektorok és alkalmazásaik
EP1560025A3 (en) * 2003-10-03 2011-09-07 F. Hoffmann-La Roche AG Specific markers for diabetes
US8088579B2 (en) 2005-02-14 2012-01-03 University Of Iowa Research Foundation Complement factor H for diagnosis of age-related macular degeneration
EP3085389A1 (en) 2005-04-07 2016-10-26 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
WO2006132118A1 (ja) 2005-06-09 2006-12-14 Matsushita Electric Industrial Co., Ltd. 振幅誤差補償装置及び直交度誤差補償装置
PT2500030E (pt) * 2005-11-04 2015-09-24 Genentech Inc Uso de inibidores da via do complemento para tratar doenças oculares
WO2007120542A2 (en) 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid library and aav capsid proteins
PT2044111E (pt) * 2006-06-21 2014-11-12 Univ Colorado Regents Abordagem seletiva do fator h do complemento para o tratamento de doenças
GB0701213D0 (en) * 2007-01-23 2007-02-28 Univ Cardiff Factor H polymorphisms in the diagnosis and therapy of inflammatory diseases such as age-related macular degeneration
KR101010352B1 (ko) 2008-05-30 2011-01-25 삼성중공업 주식회사 전력 제어 장치 및 방법
US9815876B2 (en) * 2010-03-05 2017-11-14 Omeros Corporation Chimeric inhibitor molecules of complement activation
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
KR20130040844A (ko) 2010-03-29 2013-04-24 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 약학적으로 유발된 전이유전자 제거 시스템
MX2012014975A (es) * 2010-06-22 2013-03-12 Univ Colorado Regents Anticuerpos al fragmento c3d de componente 3 de complemento.
ES2741502T3 (es) 2013-02-08 2020-02-11 Univ Pennsylvania Cápside de AAV8 modificada para la transferencia génica para terapias de retina
WO2015012924A2 (en) 2013-04-29 2015-01-29 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
ES2523016B1 (es) * 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
KR101591823B1 (ko) * 2013-12-27 2016-02-04 재단법인 목암생명공학연구소 증가된 유전자 발현능을 갖는 발현벡터
US12221615B2 (en) 2015-08-06 2025-02-11 The Trustees Of The University Of Pennsylvania GLP-1 and use thereof in compositions for treating metabolic diseases
EP3359663A4 (en) * 2015-09-24 2019-08-14 The Trustees of The University of Pennsylvania COMPOSITION AND METHOD FOR THE TREATMENT OF A COMPLEMENT-MEDIATED DISEASE
GB201519086D0 (en) * 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
AU2016375183B2 (en) * 2015-12-23 2021-01-21 eleva GmbH Polypeptides for inhibiting complement activation
KR102799528B1 (ko) * 2016-07-08 2025-04-23 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Rdh12가 연루된 장애 및 질환의 치료를 위한 방법 및 조성물
US20240254177A1 (en) * 2018-08-22 2024-08-01 Alexion Pharmaceuticals, Inc. COMPLEMENT FACTOR H AND Fc BINDING DOMAIN FUSION PROTEINS
WO2020157274A1 (en) * 2019-01-31 2020-08-06 Albert-Ludwigs-Universität Freiburg Methods for optimizing heterologous gene expression
CN113924313A (zh) 2019-04-10 2022-01-11 马萨诸塞大学 因子h载体及其用途
CN117947041A (zh) * 2022-10-28 2024-04-30 上海瑞宏迪医药有限公司 编码重组补体因子h多肽的核酸分子及用途
CN121311596A (zh) * 2023-04-07 2026-01-09 4D分子治疗有限公司 用于治疗补体病症的aav变体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515474A (ja) 2009-12-24 2013-05-09 ザ ユニヴァーシティ コート オブ ザ ユニヴァーシティ オブ エディンバラ 組換え体ｈ因子ならびにそのバリアントおよびコンジュゲート
US20150110766A1 (en) 2012-03-19 2015-04-23 University Ulm Regulator of complement activation and uses thereof
WO2015092335A2 (fr) 2013-12-20 2015-06-25 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Proteines recombinantes possedant une activite de facteur h

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ｄｒｕｇ Ｄｉｓｃｏｖｅｒｙ Ｓｙｓｔｅｍ （２００７） Ｖｏｌ．２２－６， ｐｐ．６４３－６５０
坂田洋一，血友病遺伝子治療の最新情報と展望，Ｈｅｍｏｐｈｉｌｉａ Ｔｏｐｉｃｓ （２００７）Ｖｏｌ．１３， ｐｐ．１－４， バイエル薬品株式会社 ［ｏｎｌｉｎｅ］， ［検索日 ２０２０．７．１４］，ＵＲＬ，＜ｈｔｔｐｓ：／／ｐｈａｒｍａ－ｎａｖｉ．ｂａｙｅｒ．ｊｐ／ｈｅｍｏｐｈｉｌｉａ／ｓｔａｔｉｃ／ｐｄｆ／ｄｉｓｅａｓｅ＿ｉｎｆｏ／ｈｅｍｏｐｈｉｌｉａ＿ｔｏｐｉｃｓ／ｖｏｌ１３．ｐｄｆ＞

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023139256A (ja) * 2015-09-24 2023-10-03 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 補体媒介性疾患を処置するための組成物及び方法

Also Published As

Publication number Publication date
AU2023201582A1 (en) 2023-04-13
US20210171592A1 (en) 2021-06-10
IL296929B1 (en) 2025-03-01
RU2018114907A (ru) 2019-10-24
US10988519B2 (en) 2021-04-27
JP2022000017A (ja) 2022-01-04
JP2018527941A (ja) 2018-09-27
RU2018114907A3 (enExample) 2020-02-26
JP2025029082A (ja) 2025-03-05
IL258024B (en) 2022-11-01
CA2999299A1 (en) 2017-03-30
KR20180055872A (ko) 2018-05-25
AU2023201582B2 (en) 2025-11-13
EP3359663A4 (en) 2019-08-14
IL258024A (en) 2018-05-31
CN108291216A (zh) 2018-07-17
RU2727411C2 (ru) 2020-07-21
AU2016326627B2 (en) 2022-12-15
US12180254B1 (en) 2024-12-31
IL296929B2 (en) 2025-07-01
AU2016326627A1 (en) 2018-04-05
AU2026201080A1 (en) 2026-03-05
HK1251482A1 (zh) 2019-02-01
EP3359663A2 (en) 2018-08-15
JP7324253B2 (ja) 2023-08-09
US20250051408A1 (en) 2025-02-13
CN115976105A (zh) 2023-04-18
KR102773865B1 (ko) 2025-03-04
IL258024B2 (en) 2023-03-01
WO2017053732A3 (en) 2017-05-11
JP2023139256A (ja) 2023-10-03
US20190177381A1 (en) 2019-06-13
WO2017053732A2 (en) 2017-03-30
IL296929A (en) 2022-12-01
CN108291216B (zh) 2022-09-16

Similar Documents

Publication Publication Date Title
JP7324253B2 (ja) 補体媒介性疾患を処置するための組成物及び方法
JP7280853B2 (ja) コレステロールレベルを低下させるためのｌｄｌｒ変異体および組成物中でのそれらの使用
EP3116900B1 (en) Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency
CN109328076B (zh) 补体介导的病症的治疗
CN108347932A (zh) 用于治疗遗传性眼病的方法和组合物
KR20170084012A (ko) 지혈 장애의 치료를 위한 변이체 인자 viii의 패키징 및 발현을 위한 개선된 발현 카세트
CN118108862B (zh) 抗血管新生的融合蛋白及其应用
JP2020019813A (ja) 補体関連障害を処置するための組成物、方法およびキット
JP2025134821A (ja) ＤＮＡｓｅ１および／またはＤＮＡｓｅ１Ｌ３欠失に起因するかまたは関連する疾患または障害を、処置する、寛解させる、および／または予防するための組成物および方法
AU2024250682B2 (en) Aav variants for treatment of complement disorders
HK40086178A (zh) 用於治疗补体介导的疾病的组合物和方法
BR112018005684B1 (pt) Vetor viral recombinante, composição farmacêutica e seus usos
BR122021012149B1 (pt) Plasmídeo para expressão de uma variante da proteína fh com estabilidade melhorada
KR20220062577A (ko) Tfeb의 활성화에 의해 망막 색소 상피 세포의 리소좀 기능을 회복시키는 방법
BR112017017867B1 (pt) Proteína do capsídeo do vírus adenoassociado modificado (aav), sequência de ácido nucleico, partícula de vetor viral, composição farmacêutica, bem como usos do vetor viral

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190920

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200722

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210805

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210805

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210817

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210818

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20211001

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20211006

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220629

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221206

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20230208

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20230315

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20230315

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230410

R150 Certificate of patent or registration of utility model

Ref document number: 7261583

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250